Recursion Pharmaceuticals, Inc.

RXRX

$3.44

+1.78%

N/A+$0.06

Healthcare

Biotechnology

NASDAQ

Active Trading

Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery ...

Financial Highlights of RXRX

Profitability trend

Latest / TTM · 6 periods

Gross Margin

-46.7%

Net Margin

-945.9%

P/E Ratio

-3.31x

n/a

Debt / Equity

0.07

n/a

Current Ratio

5.03

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Financial highlights

Latest / TTM · 6 periods

Snapshot

Latest / TTM: 2026-09-04

Gross Margin

-46.7%

Net Margin

-945.9%

P/E Ratio

-3.31x

Debt / Equity

0.07

Profitability

Profitability table

Metric	2021	2022	2023	2024	2025	2026
Gross MarginGross profit as a percentage of revenue.	100.0%	-21.7%	2.9%	23.1%	-62.0%	—
Operating MarginOperating income as a percentage of revenue.	-1827.8%	-619.3%	-797.8%	-814.1%	-867.9%	—
Net MarginNet income as a percentage of revenue.	-1864.8%	-603.5%	-747.7%	-788.0%	-863.4%	—
EBITDA MarginEBITDA divided by revenue.	-1751.2%	-573.7%	-701.1%	-725.2%	-749.0%	—
Pre-tax MarginPre-tax profit as a percentage of revenue.	-1864.8%	-603.5%	-757.0%	-789.9%	-863.5%	—

Liquidity & leverage

Liquidity & leverage table

Metric	2021	2022	2023	2024	2025	2026
Current RatioCurrent assets divided by current liabilities.	11.46	5.68	4.70	3.81	5.50	—
Quick RatioLiquid assets divided by current liabilities.	11.46	5.68	4.70	3.81	5.50	—
Cash RatioCash and equivalents divided by current liabilities.	6.11	5.48	4.20	3.17	5.03	—
Debt / AssetsDebt as a share of total assets.	1.9%	7.3%	7.8%	7.5%	5.3%	—
Debt / EquityDebt compared with shareholder equity.	0.02	0.10	0.11	0.10	0.07	—

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	2026
Receivables TurnoverHow often receivables are collected in a year.	1.10x	14.41x	14.18x	1.20x	3.03x	—
Inventory TurnoverHow often inventory is sold in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Payables TurnoverHow often payables are paid in a year.	0.00x	10.53x	10.77x	2.09x	6.68x	—
Asset TurnoverRevenue generated per dollar of assets.	0.02x	0.06x	0.07x	0.04x	0.05x	—
Working Capital TurnoverRevenue generated per dollar of working capital.	0.03x	0.08x	0.11x	0.13x	0.13x	—

Valuation ratios

Valuation ratios table

Metric	2021	2022	2023	2024	2025	2026
P/E RatioPrice paid for each dollar of earnings.	-16.31x	-5.67x	-6.24x	-4.00x	-2.84x	—
P/B RatioPrice paid for each dollar of book value.	5.37x	2.79x	4.42x	1.79x	1.62x	—
P/S RatioPrice paid for each dollar of sales.	291.68x	34.11x	46.71x	31.50x	24.50x	—
P/FCF RatioPrice paid for each dollar of free cash flow.	-14.70x	-11.20x	-6.82x	-4.97x	-4.84x	—
Dividend YieldAnnual dividend divided by current share price.	0.0%	0.0%	0.0%	0.0%	0.0%	—

Supply Chain of RXRX

RELATIONS

Upstream

NVIDIA CorporationNASDAQ:NVDA Google Cloud (Alphabet Inc.)NASDAQ:GOOGL Molecular Devices (Danaher Corporation subsidiary)NYSE:DHR Beckman Coulter (Danaher Corporation subsidiary)NYSE:DHR Tempus AI, Inc.NASDAQ:TEMHelix (Helix OpCo LLC)Splunk (Cisco Systems, Inc.)NASDAQ:CSCO Thermo Fisher Scientific Inc.NYSE:TMO Taiwan Semiconductor Manufacturing Company (TSMC)NYSE:TSM

Downstream

Roche Holding AG / GenentechSIX:ROGSanofi S.A.NASDAQ:SNYBayer AGXTRA:BAYNMerck KGaAXTRA:MRK

Proxies

Schrödinger, Inc.NASDAQ:SDGR Relay Therapeutics, Inc.NASDAQ:RLAYExscientia plc (former)UnconfirmedAbCellera Biologics, Inc.NASDAQ:ABCL

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer